R&D

Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 2017

December 11, 2017

RIDGEFIELD, Conn. & INGELHEIM, Germany–(BUSINESS WIRE)–2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming the lives of patients and winning the fight against cancer. External partnerships complement Boehringer Ingelheim’s two-pronged research strategy – investigating both cancer cell-directed therapies and immune cell-directed […]

Altimmune Submits Investigational New Drug Application for NasoShield in Preparation for its Phase 1 Trial

December 11, 2017

GAITHERSBURG, Md., Dec. 11, 2017 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for NasoShield, the Company’s next generation anthrax vaccine. In animal models, a single dose of NasoShield induces rapid and durable […]

Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology Conference

December 11, 2017

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced interim Phase 1/2 data on its subcutaneously administered, prophylactic Factor IX variant CB 2679d/ISU304 in an oral presentation at the 59th American Society of Hematology (ASH) […]

Samumed Doses First Patient in Phase 1 Trial of SM08502 for Treatment of Advanced Solid Tumors

December 11, 2017

SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) — Samumed, LLC, today announced the dosing of the first cancer patient in its Phase 1 trial of SM08502, a small molecule Wnt pathway inhibitor in oral tablet formulation. This Phase 1, open-label, multi-center, dose-escalation study will evaluate the safety, tolerability and pharmacokinetics (PK) of orally administered SM08502 […]

Caelum Biosciences Announces Positive Phase 1a/1b Data Demonstrating CAEL-101 (mAb 11-1F4) Improves Organ Function in AL Amyloidosis

December 11, 2017

NEW YORK, Dec. 11, 2017 (GLOBE NEWSWIRE) — Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (NASDAQ:FBIO) Company focused on developing treatments for rare and life-threatening diseases, today announced full Phase 1a/1b clinical data demonstrating CAEL-101’s (mAb 11-1F4) ability to bind to light-chain amyloid fibrils and achieve early and clinically efficacious organ responses in patients […]

Fate Therapeutics Announces First Subject Treated with FATE-NK100 in APOLLO Study for Recurrent Ovarian Cancer

December 11, 2017

SAN DIEGO, Dec. 08, 2017 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the first subject has been treated in the APOLLO study of FATE-NK100 in women with ovarian cancer resistant to, or recurrent on, platinum-based […]

Fate Therapeutics Announces First Subject Treated with FATE-NK100 in APOLLO Study for Recurrent Ovarian Cancer

December 11, 2017

SAN DIEGO, Dec. 08, 2017 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the first subject has been treated in the APOLLO study of FATE-NK100 in women with ovarian cancer resistant to, or recurrent on, platinum-based […]

Akari Therapeutics Announces Phase II COBALT trial of Coversin™ in Patients with PNH Met the Primary Endpoint

December 11, 2017

NEW YORK and LONDON, Dec. 08, 2017 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announced that the three additional patients that were enrolled into the Phase II COBALT trial of CoversinTM in paroxysmal nocturnal hemoglobinuria […]

Apellis Pharmaceuticals Presents Update on Phase 1b PHAROAH Trial of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) at Annual Scientific Assembly of the International PNH Interest Group (IPIG)

December 11, 2017

LOUISVILLE, Ky. and CAMBRIDGE Mass., Dec. 08, 2017 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, will present an update on its Phase 1b PHAROAH trial at the 12th Annual Scientific Assembly of the International PNH Interest Group (IPIG) […]

Lilly Reports Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 Study in First-Line Advanced Gastric Cancer

December 11, 2017

INDIANAPOLIS, Dec. 8, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced top-line results from its Phase 3 RAINFALL study of CYRAMZA® (ramucirumab) in combination with cisplatin and capecitabine or 5-FU (5-fluorouracil) in the first-line treatment of patients with HER2-negative metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. The trial met its primary endpoint […]

BeiGene Presents Updated Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) Combined with GAZYVA® (Obinutuzumab) at the 59th American Society of Hematology Annual Meeting

December 11, 2017

CAMBRIDGE, Mass. and BEIJING, China, Dec. 09, 2017 (GLOBE NEWSWIRE) — BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today presented updated preliminary clinical data from an ongoing Phase 1b trial of its investigational Bruton’s Tyrosine Kinase (BTK) inhibitor zanubrutinib […]

Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology Conference

December 11, 2017

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced interim Phase 1/2 data on its subcutaneously administered, prophylactic Factor IX variant CB 2679d/ISU304 in an oral presentation at the 59th American Society of Hematology (ASH) […]

Sprycel (dasatinib) Added to Standard Chemotherapy Demonstrates Three-Year Survival Benefit in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

December 11, 2017

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced data from the phase 2 CA180-372 study in pediatric patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) treated with Sprycel (dasatinib) added to a chemotherapy regimen modelled on a Berlin-Frankfurt-Munster high-risk backbone. The combination demonstrated an event-free survival (EFS) rate, the study’s primary endpoint, […]

BeiGene Presents Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) in Non-Hodgkin’s Lymphoma at the 59th American Society of Hematology Annual Meeting

December 11, 2017

CAMBRIDGE, Mass. and BEIJING, China, Dec. 09, 2017 (GLOBE NEWSWIRE) — BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today presented preliminary clinical data from an ongoing Phase 1b trial of its investigational Bruton’s Tyrosine Kinase (BTK) inhibitor zanubrutinib (BGB-3111) […]

Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8αβ+ T Cells from Clonal Engineered Master Pluripotent Cell Line for Off-the-Shelf T-cell Immunotherapy

December 11, 2017

SAN DIEGO, Dec. 09, 2017 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today the generation of chimeric antigen receptor (CAR)-targeted CD8αβ+ T cells from a clonal engineered master pluripotent cell line (MPCL). The clonal engineered MPCL was created […]

Bellicum Announces Data Presentation Demonstrating Improved Immune Recovery Following Haploidentical Stem Cell Transplant with BPX-501 in Children with Blood Cancers and Nonmalignant Diseases

December 11, 2017

ATLANTA, Dec. 09, 2017 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced results from a leading European transplant center participating in the BP-004 trial in children with blood cancers and nonmalignant disorders. Patients were treated with BPX-501 following an […]

Combination of G100 with KEYTRUDA (pembrolizumab) Triggers Robust Systemic Responses in Follicular NHL Patients

December 11, 2017

SEATTLE and SOUTH SAN FRANCISCO, Calif., Dec. 10, 2017 (GLOBE NEWSWIRE) — Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today presented data from the randomized Phase 2 trial of its investigational intratumoral TLR4 agonist G100 plus low-dose radiation (G100 Monotherapy) with or without KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in follicular non-Hodgkin’s lymphoma […]

Kura Oncology Reports Positive Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia

December 11, 2017

SAN DIEGO, Dec. 10, 2017 (GLOBE NEWSWIRE) — Kura Oncology, Inc., (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today reported positive, preliminary results from a Phase 2 clinical study of its lead candidate tipifarnib in patients with chronic myelomonocytic leukemia (CMML). The data were presented today at the […]

FEEDBACK